Dermatologic Emergencies

dermatology-emergencieskapak-1-0-25

Toxic Epidermal Necrolysis

Serkan ŞAHİN
Health Sciences University Faculty of Medicine, Ankara Bilkent City Hospital, Department of Emergency Medicine, Ankara, Türkiye

Şahin S. Toxic epidermal necrolysis. In: Oğuztürk H, Görmeli Kurt N, eds. Dermatologic Emergencies. 1st ed. Ankara: Türkiye Klinikleri; 2025. p.15-20.

ABSTRACT Toxic epidermal necrolysis (TEN) is a rare, life-threatening condition characterized by extensive epidermal detachment, mucositis, and systemic involvement. It most commonly results from adverse drug reactions, with high-risk medications including allopurinol, lamotrigine, and sulfonamides. The disease typically presents with prodromal symptoms like fever, malaise, and sore throat, followed by the rapid onset of mucocutaneous lesions. TEN affects over 30% of the body surface area and is associated with significant morbidity and mortality, especially in immunocompromised individuals. Man- agement of TEN requires a multidisciplinary approach in specialized burn or intensive care units. Prompt identification and discontinuation of the causative agent are critical, alongside aggressive supportive care, including fluid resuscitation and pain management. Therapeutic interventions vary, including surgical debridement and conservative approaches for skin care. Despite advancements, the pathogenesis of TEN is still not fully understood, highlighting the need for further research into its underlying mecha- nisms and optimal treatment strategies.

Drug-related side effects and adverse reactions; drug effects; drug hypersensitivity; dermatology; emergency medical service

Referanslar

  1. Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol. 1956;68(11):355-61. [Crossref]  [PubMed]
  2. Letko E, Papaliodis D, Papaliodis G, Daoud Y, Ahmed A, Foster C. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy, Asthma Immunol. 2005;94(4):419-36. [Crossref]  [PubMed]
  3. Bellón T. Mechanisms of severe cutaneous adverse reactions: recent advances. Drug Saf. 2019;42(8):973-92. [Crossref]  [PubMed]
  4. Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, Harr T. Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis. Clin Rev Allergy Immunol. 2018;(54):147-76. [Crossref]  [PubMed]
  5. Hsu D, Brieva J, Silverberg N, Silverberg J. Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults. J Invest Dermatol. 2016;136(7):1387-97. [Crossref]  [PubMed]
  6. Hsu D, Brieva J, Silverberg N, Paller A, Silverberg J. Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States. J Am Acad Dermatol. 2017;76(5):811-7. [Crossref]  [PubMed]  [PMC]
  7. Sekula P, Dunant A, Mockenhaupt M, Naldi L, Bavinck J, Halevy S, et al. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Investig Dermatology. 2013;133(5):1197-204. [Crossref]  [PubMed]
  8. Frey N, Jossi J, Bodmer M, Bircher A, Jick S, Meier C, et al. The epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK. J Invest Dermatol. 2017;137(6):1240-7. [Crossref]  [PubMed]
  9. Woolum J, Bailey A, Baum R, Metts E. A review of the management of Stevens-Johnson syndrome and toxic epidermal necrolysis. Adv Emerg Nurs J. 2019;41(1):56-64. [Crossref]  [PubMed]
  10. Charlton O, Harris V, Phan K, Mewton E, Jackson C, Cooper A. Toxic epidermal necrolysis and Steven-Johnson syndrome: a comprehensive review. Adv wound care. 2020;9(7):426-39. [Crossref]  [PubMed]  [PMC]
  11. Torres‐Navarro I, Briz-Redón Á, Botella‐Estrada R. Systemic therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: a SCORTENbased systematic review and meta‐analysis. J Eur Acad Dermatology Venereol. 2021;35(1):159-71. [Crossref]  [PubMed]
  12. Van der Poll T, de Jonge E, Levi M. Regulatory role of cytokines in disseminated intravascular coagulation. Semin Thromb Hemost. 2001;27(6):639-51. [Crossref]  [PubMed]
  13. Chen C, Hsu T, Hui R, Lu C, Chen W, Chiang P. Taiwan Severe Cutaneous Adverse Reaction Consortium. Disseminated intravascular coagulation in Stevens-Johnson syndrome and toxic epidermal necrolysis. J Am Acad Dermatol. 2021;84(6):1782-91. [PubMed]
  14. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bavinck J, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCARstudy. J Investig Dermatology. 2008;128(1):35-44. [Crossref]  [PubMed]
  15. Roujeau J, Kelly J, Naldi L, Rzany B, Stern R, Anderson T, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333(24):1600-7. [Crossref]  [PubMed]
  16. Saw S, Lee H, Ng Q. Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients. Eur J Cancer. 2017;(81):237-9. [Crossref]  [PubMed]
  17. Ball R, Ball L, Wise R, Braun M, Beeler J, Salive M, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis after vaccination: reports to the vaccine adverse event reporting system. Pediatr Infect Dis J. 2001;20(2):219- 23. [Crossref]  [PubMed]
  18. Kinoshita Y, Saeki H. A review of the pathogenesis of toxic epidermal necrolysis. J Nippon Med Sch. 2016;83(6):216-22. [Crossref]  [PubMed]
  19. Das KK, Khondokar S, Rahman A, Chakraborty A. Unidentified drugs in traditional medications causing toxic epidermal necrolysis: a developing country experience. Int J Dermatol. 2014;53(4):510-5. [Crossref]  [PubMed]
  20. Callan H, Jenkins R, Maggs J, Lavergne S, Clarke S, Naisbitt D, et al. Multiple adduction reactions of nitroso sulfamethoxazole with cysteinyl residues of peptides and proteins: implications for hapten formation. Chem Res Toxicol. 2009;22(5):937-48. [Crossref]  [PubMed]
  21. Yang C, Hung S, Juo C, Lin Y, Fang W, Lu IH, et al. HLA-B∗ 1502-bound peptides: Implications for the pathogenesis of carbamazepine-induced StevensJohnson syndrome. J Allergy Clin Immunol. 2007;120(4):870-7. [Crossref]  [PubMed]
  22. Dodiuk-Gad R, Chung W, Valeyrie-Allanore L, Shear N. Stevens-Johnson syndrome and toxic epidermal necrolysis: an update. Am J Clin dermatology. 2015;16(6):475-93. [Crossref]  [PubMed]
  23. Chung W, Wang C, Dao R. Severe cutaneous adverse drug reactions. J Dermatology. 2016;43(7):758-66. [Crossref]  [PubMed]
  24. Correia O, Delgado L, Ramos J, Resende C, Torrinha J. Cutaneous T-cell recruitment in toxic epidermal necrolysis: further evidence of CD8+ lymphocyte involvement. Arch Dermatol. 1993;129(4):466-8. [Crossref]  [PubMed]
  25. Tohyama M, Watanabe H, Murakami S, Shirakata Y, Sayama K, Iijima M, et al. Possible involvement of CD14+ CD16+ monocyte lineage cells in the epidermal damage of Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatology. 2012;166(2):322-30. [Crossref]  [PubMed]
  26. Duong T, Valeyrie-Allanore L, Wolkenstein P, Chosidow O. Severe cutaneous adverse reactions to drugs. Lancet. 2017;390(10106):1996-2011. [Crossref]  [PubMed]
  27. Roujeau J, Chosidow O, Saiag P, Guillaume J. Toxic epidermal necrolysis (Lyell syndrome). Am Acad Dermatol. 1990;23(6):1039-58. [Crossref]  [PubMed]
  28. Morales M, Purdue G, Verity S, Arnoldo B, Blomquist P. Ophthalmic manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis and relation to SCORTEN. Am J Ophthalmol. 2010;150(4):505-10. [Crossref]  [PubMed]
  29. Hung C, Liu W, Kuo M, Lee C, Hwang S, Chen H. Acute renal failure and its risk factors in Stevens-Johnson syndrome and toxic epidermal necrolysis. Am J Nephrol. 2009;29(6):633-8. [Crossref]  [PubMed]
  30. Griffiths C, Barker J, Bleiker T, Chalmers R, Creamer D. Rook's Textbook of Dermatology. 9th ed. John Wiley & Sons; 2016. [Link]
  31. Revuz J, Penso D, Roujeau J, Guillaume J, Payne C, Wechsler J, et al. Toxic epidermal necrolysis: clinical findings and prognosis factors in 87 patients. Arch Dermatol. 1987;123(9):1160-5. [Crossref]  [PubMed]
  32. Bastuji-Garin S, Rzany B, Stern R, Shear N, Naldi L, Roujeau J. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92-6. [Crossref]  [PubMed]
  33. Fouchard N, Bertocchi M, Roujeau J, Revuz J, Wolkenstein P, Bastuji-Garin S. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115(2):149-53. [Crossref]  [PubMed]
  34. Rzany B, Hering O, Mockenhaupt M, Chröder W, Goerttler E, Ring J, et al. Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 1996;135(1):6-11. [Crossref]  [PubMed]
  35. Creamer D, Walsh S, Dziewulski P, Exton L, Lee H, Dart J, et al. UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. Br J Dermatol. 2016;174(6):1194-227. [Link]
  36. Watanabe Y, Watanabe T, Yamaguchi Y. Anti-SS-A antibody is a potential predictor of severe Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective cohort study. J Am Acad Dermatol. 2024;90(2):385-7. [Crossref]  [PubMed]
  37. Schulz J, Sheridan R, Ryan C, MacKool B, Tompkins R. A 10-year experience with toxic epidermal necrolysis. J Burn Care Rehabil. 2000;21(3):199- 204. [Crossref]  [PubMed]
  38. Shiga S, Cartotto R. What are the fluid requirements in toxic epidermal necrolysis? J Burn Care Res. 2010;31(1):100-4. [Crossref]  [PubMed]
  39. Coss‐Bu J, Jefferson L, Levy M, Walding D, David Y, Klish W. Nutrition requirements in patients with toxic epidermal necrolysis. Nutr Clin Pract. 1997;12(2):81-4. [Crossref]  [PubMed]
  40. Ingen-Housz-Oro S, Duong T, Bensaid B, Bellon N, Lu D. Epidermal necrolysis French national diagnosis and care protocol (PNDS; protocole national de diagnostic et de soins). Orphanet J Rare Dis. 2018;13(1):56. [Crossref]  [PubMed]  [PMC]
  41. Spies M, Sanford A, Low J, Wolf S, Herndon D. Treatment of extensive toxic epidermal necrolysis in children. Pediatrics. 2001;108(5):1162-8. [Crossref]  [PubMed]
  42. Lee N, Ko W, Hsueh P. Nanoparticles in the treatment of infections caused by multidrug-resistant organisms. Front Pharmacol. 2019;10:1153. [Crossref]  [PubMed]  [PMC]